<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318406</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-2410</org_study_id>
    <nct_id>NCT03318406</nct_id>
  </id_info>
  <brief_title>Post-Market BTVA Registry</brief_title>
  <official_title>Post-Market BTVA Registry for Patients With Emphysema Treated With BTVA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uptake Medical Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>acromion GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Uptake Medical Technology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System
      is indicated for treatment of patients with heterogeneous upper lobe emphysema. This study is
      a retrospective and prospective, observational, multi-center, post-market registry of
      patients prescribed InterVapor. The primary objective of the Registry is to describe the
      long-term impact of InterVapor treatment on patient quality of life (QOL) in a real-world
      setting. After InterVapor treatment, patients will be followed for 5 years as per the
      standard of care and safety and efficacy data (quality of life, pulmonary function, exercise
      capacity) collected as part of the registry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BTVA Registry will enroll up to 300 patients with upper lobe predominant emphysema that
      are being treated with BTVA at sites located in the EU and other select geographies. Patients
      will be followed as per standard of care and the registry will collect follow-up data for
      five years following treatment. The follow up data collected will include pulmonary function
      measurements (spirometry, body plethysmography, and diffusing capacity for carbon monoxide),
      exercise capacity (six minute walk test), imaging findings (chest x-ray and CT), and a
      quality of life questionnaire (SGRQ-C). All serious and non-serious adverse events will also
      be collected for the duration of the study in order to assess safety. Serious adverse events
      will be adjudicated by an independent medical monitor in order to establish relatedness to
      the InterVapor device and procedure.

      Descriptive statistics will be used to summarize all safety and effectiveness data. There is
      no predefined hypothesis regarding the magnitude of effectiveness of InterVapor or the
      incidence of specific safety outcomes.

      Monitoring of the registry study will be undertaken as a continuous process to ensure that
      high-quality data are obtained and to ensure compliance with registry procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in Quality of Life score as assessed by the SGRQ-C questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>procedure and device related serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in Forced Expired Volume in 1 second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RV</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in Residual Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLCO</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in Diffusing capacity of the lung for carbon monoxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Tolerance</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in six minute walk distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung volume reduction</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>change in lung volume assessed by CT</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in FVC</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in forced vital capacity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in TLC</measure>
    <time_frame>Baseline 12 months</time_frame>
    <description>Change in otal lung capacity</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Emphysema or COPD</condition>
  <arm_group>
    <arm_group_label>BTVA treated patients</arm_group_label>
    <description>Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bronchoscopic thermal vapor ablation</intervention_name>
    <description>Bronchoscopic vapor delivery to airway segment(s) targeted for treatment</description>
    <arm_group_label>BTVA treated patients</arm_group_label>
    <other_name>BTVA</other_name>
    <other_name>InterVapor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with upper lobe predominant emphysema being evaluated for possible InterVapor
        treatment will be considered for enrollment in the Registry
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients will have heterogeneous emphysema, as evidenced by high-resolution computed
             tomography (HRCT) demonstrating a heterogeneity index &gt;1.2 in at least one segment to
             be treated

          2. Patients must be &gt; 18 years of age

          3. Patients are required to provide informed consent prior to inclusion in the Registry

        Exclusion Criteria:

          1. FEV1 &lt; 20% predicted

          2. DLCO &lt; 20% predicted

          3. Inability to walk &gt; 140 meters in 6 minutes (6MWD) following optimized medical
             management

          4. Unstable COPD (any of the following):

               1. &gt; 3 COPD related hospitalizations requiring antibiotics in past 12 months

               2. COPD related hospitalization in past 3 months

               3. daily use of systemic steroids, i.e. &gt; 5 mg prednisolone

          5. Concomitant illnesses or medications that would pose a significant increased risk for
             complications following treatment with InterVapor. Examples of particular relevance
             include: immune system disorders, immunosuppressant medications of clinical relevance,
             bleeding disorders and unstable cardiovascular conditions, history of asthma or
             alpha-1 antitrypsin deficiency

          6. Newly prescribed morphine derivatives within the last 4 weeks

          7. Pregnant or breastfeeding

          8. Highly diseased lower lobes (tissue to air ratio of &lt;11%)

          9. Bacterial infection or symptoms indicative of active infection (i.e., fever, elevated
             white blood cell count)

         10. Presence of single large bulla (defined as &gt; 1/3 volume of lobe) or a paraseptal
             distribution of emphysema in the treated lobe

         11. Recent respiratory infections or COPD exacerbation in preceding 6 weeks -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Herth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik University of Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordan Low</last_name>
    <phone>206 926-7408</phone>
    <email>jlow@uptakemedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Arneson</last_name>
    <phone>206 926 7408</phone>
    <email>jarneson@uptakemedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Otto-Wagner Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Duller</last_name>
      <email>blvr.koordinator@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Arschang Valipour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claus Steppert, MD, MHBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christian Witt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13352</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ralf-Harto Huebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Havelhöhe</name>
      <address>
        <city>Berlin</city>
        <zip>14089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Grah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Coswig</name>
      <address>
        <city>Coswig</city>
        <zip>01640</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dirk Koschel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik - West German Lung Center</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kaid Darwiche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>Gauting</city>
        <zip>D-82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wolfgang Gesierich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stephan Eisenmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinikum Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christoph Petermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Felix Herth, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralf Eberhardt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Gompelmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Franz Stanzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jürgen Heck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lungenfachklinik Immenhausen</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Hammerl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruppiner Kliniken</name>
      <address>
        <city>Neuruppin</city>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hagen Kelm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manfred Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marek Lommatzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus vom Roten Kreuz Bad Cannstatt</name>
      <address>
        <city>Stuttgart</city>
        <zip>70372</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Martin Hetzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae</name>
      <address>
        <city>Dublin</city>
        <zip>7 D07R2WY</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jim Egan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Tamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tino Schneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Brutsche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Czechia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>registry</keyword>
  <keyword>vapor ablation</keyword>
  <keyword>InterVapor</keyword>
  <keyword>BTVA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

